Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 PANTHER trial.
Matikas A, Papakonstantinou A, Loibl S, Steger GG, Untch M, Johansson H, Tsiknakis N, Hellström M, Greil R, Möbus V, Gnant M, Bergh J, Foukakis T.
Matikas A, et al. Among authors: johansson h.
Lancet Reg Health Eur. 2024 Dec 3;49:101162. doi: 10.1016/j.lanepe.2024.101162. eCollection 2025 Feb.
Lancet Reg Health Eur. 2024.
PMID: 39703564
Free PMC article.